PT-141 Benefits and Research Applications
What is PT-141? PT-141 is a code name used during the developmental phase of bremelanotide, a peptide derivative of thyroxine that acts as a melanocortin receptor agonist. PT-141 was originally developed by Palatin Technologies, which funded initial Phase 3 clinical studies. In 2019, PT-141 received US FDA approval for the …